Israel Healthcare Ventures (IHCV)

Israel Healthcare Ventures, known as IHCV, is one of the earliest dedicated medical venture funds in Israel, with a mandate focused entirely on clinical-stage devices, therapeutics, and biotech platforms. The Tel Aviv-based firm is positioned squarely as a specialist healthcare investor rather than a generalist with a healthcare line item, which means founders can expect diligence anchored in clinical evidence, regulatory strategy, and reimbursement rather than software metrics alone. The firm is identified by its specialty score in the source data as one of the more focused entries in this batch.

Stages span Series A through Series C, with check sizes in the $5 million to $25 million range. Sub-verticals include medical devices, biotech, and diagnostics. The record does not list specific portfolio companies, but the firm’s longevity in the Israeli healthcare ecosystem suggests deep co-investor relationships with local life sciences syndicates and global strategics in pharma and devtech.

For founders, IHCV is most useful past the early scientific risk phase, when a device or therapeutic asset has clinical data and a clear path through FDA, CE Mark, or equivalent regulatory milestones. Pure software AI products without a hardware or therapeutic anchor are less likely to fit. Israeli HQ or strong Israeli clinical ties will make the conversation easier, and founders should arrive with a syndication plan that matches the firm’s check size against the round’s overall need.